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Abstract
Background: The ability to culture Mycobacterium tuberculosis from clinical specimens serves as
the gold standard for the diagnosis of tuberculosis. However, a number of false-positive diagnoses
may be due to cross-contamination of such specimens. We herein investigate such episode of
cross-contamination by using a technique known as multispacer sequence typing (MST). This
technique was applied to six M. tuberculosis isolates prepared within the same laboratory over a
two-week period of time.
Results: MST analysis indicated a unique and common sequence profile between a strain isolated
from a patient with proven pulmonary tuberculosis and a strain isolated from a patient diagnosed
with lung carcinoma. Using this approach, we were able to provide a clear demonstration of
laboratory cross-contamination within just four working days. Further epidemiological
investigations revealed that the two isolates were processed for culture on the same day.
Conclusion: The application of MST has been demonstrated to serve as a rapid and efficient
method to investigate cases of possible cross-contamination with M. tuberculosis.
Background
The isolation of Mycobacterium tuberculosis complex organ-
isms from clinical specimens collected from suspected
patients serves as the gold standard for the proper diagno-
sis of tuberculosis in the laboratory [1]. However, false-
positive cultures have been reported that result from the
cross-contamination of specimens via a contaminated
bronchoscope [2,3] or, more often, by laboratory cross-
contamination [4]. The latter situation has been reported
at a frequency ranging from 0.1% to 3% of M. tuberculosis
[1,4-8]. Laboratory cross-contamination should be sus-
pected when M. tuberculosis is cultured from a smear-neg-
ative specimen processed in the same batch as a culture
from a smear-positive specimen. The factors that increase
the likelihood of cross-contamination include instances
when only one of several specimens from the same
patient is culture-positive and instances when the clini-
cian is considering a diagnosis other than tuberculosis,
which the clinician believes to be more likely based on
clinical observations [8]. Such false-positives resulting
from cross-contaminated specimens are disadvantageous
since, besides resulting in a misdiagnosis, they result in
unnecessary treatment and delay further diagnostic inves-
tigations in an effort to derive a definitive and correct
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diagnosis [9]. Finally, these false-positive cultures lead to
an overestimation of the incidence and prevalence of
tuberculosis in humans [10].
A definitive demonstration of cross-contamination can be
derived from precise molecular analyses of M. tuberculosis
isolates. M. tuberculosis isolates harbouring identical gen-
otypes are regarded as clones and are thus epidemiologi-
cally linked [11]. The most widely used technique for
determining the genotype of M. tuberculosis is a technique
known as IS6110-restriction fragment length polymor-
phism (RFLP) analysis. RFLP analysis requires a large
amount of biological material and, thus, poses a risk to
laboratory workers due to the harmful nature of this path-
ogen. Moreover, the latter method requires a substantial
amount of time due to the fastidious nature of M. tubercu-
losis [12]. More importantly from, a strictly technical per-
spective, IS6110-RFLP analysis does a poor job of
indicating the presence of M. tuberculosis when these
organisms contain only a few copies of the IS6110
sequence [13]. Recently, the variable number tandem
repeat (VNTR) PCR-based technique and the mycobacte-
rial interspersed repetitive unit (MIRU) [14] technique
have proven to be reliable methods for the resolution of
cross-contamination events [15,16].
We herein report the application of a new PCR-sequenc-
ing-based genotyping method, known as multispacer
sequence typing (MST)[17], for determining whether
specimens have been cross-contaminated with M. tubercu-
losis in the laboratory.
Case report
A 60-year-old man was admitted for an examination to
determine whether he had interstitial pneumonia. The
patient had been previously hospitalised for two weeks at
a different location with symptoms that included short-
ness of breath, a fever of 38.5°C, and a 7 kg loss of weight
within the past month. At the aforementioned hospital, a
chest radiograph indicated the presence of bilateral inter-
stitial pneumonia. Subsequent microbiological investiga-
tions, including Ziehl-Neelsen staining and a PCR-based
assay to test for the presence of M. tuberculosis on expecto-
ration, indicated that there were no signs of such an infec-
tion. The patient was then transferred to our department
for further evaluation. Clinical examination of the patient
verified both a body temperature of 38 – 38.5°C and dys-
pnoea with 90% oxygen saturation under 6 L/min oxygen.
The medical history of the patient was unremarkable,
except for previous treatment for arterial hypertension.
The total body tomodensitometry indicated the presence
of nodules in both lungs, in the mediastinal lymph nodes,
and in a right axilar lymph node. The pertinent laboratory
assays were performed and indicated a value of 5.9 leuco-
cytes/ml with 76% polymorphonuclear cells and 190
platelets/ml. The erythrocyte sedimentation rate was
determined to be 28 mm for the first hour. The lactate
dehydrogenase level was 612 IU/ml (normal levels are <
430 IU/ml), the gamma GT level was 699 IU/ml (normal
levels are < 55 IU/ml), the bilirubin concentration was 13
μmol/l, the AST level was 96 IU/l (normal values are < 25
IU/ml), and the ALT level was shown to be 127 IU/l (nor-
mal values are < 45 IU/ml). It was suspected that the
patient had already begun to develop pulmonary tubercu-
losis and thus was recommended to receive anti-tubercu-
losis therapy since it was reported that M. tuberculosis was
isolated from an expectoration that was collected 14 days
prior during the first hospital visit. Due to the observation
that the patient's respiratory status had worsened, the
patient was admitted into an intensive care unit for a
period of four days. The results of direct microscopic
examinations using Gram and Ziehl-Neelsen staining of a
surgical lung biopsy were negative. This sample, cultured
in BACTEC (Becton and Dickinson, Le Pont de La Claix,
France) and in 5% blood agar in slant tubes (Labo Mod-
erne, Dinan, France), remained sterile after a two-month
incubation period. Subsequent histological examination
discovered large B-cell lymphoma and further assess-
ments confirmed that the patient had stage IV lymphoma
that involved the lung, liver, and bone marrow. The
patient then received the appropriate anti-lymphoma
therapy.
Results and Discussion
Our investigation revealed isolation of a total of six M.
tuberculosis strains from a laboratory that performed anal-
yses for six different patients (including the index patient)
within a 2-week period before and after the isolation of M.
tuberculosis from the index patient (Figure 1). All isolates
were recovered from respiratory tract specimens and iden-
tified as M. tuberculosis by phenotypic methods and the
ETR-D sequencing method [18]. Isolate Tub1 (patient A)
was recovered from a specimen received and handled on
April 27th, while isolate Tub2 (patient B) was recovered
from a specimen received on May 3rd, but handled for set-
ting in culture on May 4th. Isolate Tub3 (index patient C)
was recovered from a specimen received and handled on
May 4th, while isolates Tub4, Tub5, and Tub6 (patients D,
E, and F, respectively) were recovered from specimens
received and handled on May 8th. Ziehl-Neelsen staining
was performed on all six specimens and the subsequent
analyses revealed the presence of acid-fast bacilli for all
samples with the exception of the specimen collected
from index patient C, which exhibited no acid-fast bacil-
lus. Epidemiological investigation indicated that patients
A, D, and E resided in the same ward, whereas no epide-
miological link was found between the other three
patients, including index patient C.BMC Microbiology 2009, 9:47 http://www.biomedcentral.com/1471-2180/9/47
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Eight intergenic spacers were PCR amplified for each of
the six M. tuberculosis isolates and yielded PCR products of
the expected sizes. Sequences derived from these PCR
products were combined and assembled for each of the six
isolates. MST analysis was completed within four working
days. Analysis of the sequence combinations determined
three new genetic profiles, including profile ST43, which
characterized the three isolates derived from patients A, D,
and E; profile ST44, which characterized the two isolates
derived from patient B and the index patient C; and pro-
file ST45, which was discovered in the isolate derived
from patient F (Figure 1). These new profiles resulted
from a novel combination of the following spacer alleles:
the ST43 profile combined alleles 1/MST1, 1/MST2, 1/
MST3, 2/MST4, 1/MST8, 3/MST11, 4/MST12, and allele 4/
MST13; the ST44 profile combined alleles 1/MST1, 1/
MST2, 2/MST3, 2/MST4, 1/MST8, 3/MST11, 4/MST12,
and allele 4/MST13; and the ST45 profile combined alle-
les 1/MST1, 1/MST2, 1/MST3, 1/MST4, 3/MST8, 3/
MST11, 4/MST12, and allele 4/MST13. The profiles for
ST43, ST44, and ST45 have been added to our free and
accessible MST database http://ifr48.timone.univ-mrs.fr/
MST_Mtuberculosis/mst. MST genotyping data were
assumed to be authentic based on the observations that
the PCR-negative controls remained negative, coupled
with the observation that all PCR products were of the
predicted size. Moreover, analysis of the spacer sequences
edited in this work identified three new profiles, clearly
indicating that amplicons did not result from laboratory
contamination as a consequence of previous experiments.
The MST genotyping data provided evidence to support
epidemiological and clinical data that confirmed labora-
tory cross-contamination. Specifically, one profile (ST43)
comprised three isolates recovered from epidemiologi-
cally-linked patients, whereas a different profile (ST45)
characterized only one isolate from a specimen collected
from an unrelated patient F. The profile ST44 was discov-
ered for two M. tuberculosis isolates obtained from the
index patient C and one unrelated patient B. Microscopic
examination of a respiratory tract specimen collected from
patient B indicated the presence of acid-fast bacilli, while
the same analysis performed for a specimen from the res-
piratory tract of the index patient C showed no indication
of acid-fast bacilli. Both of the latter two specimens were
handled in the same laboratory, on the same day, and
within the same batch of sample preparations, which
explains the observation that the specimen recovered
from the index patient (patient C) was contaminated by
the specimen collected from patient B. Such a situation
has been previously observed in cases of laboratory cross-
contamination [19,20]. Interestingly, the frequency of
false-positive cultures has been shown to be higher for
laboratories that do not process high numbers of speci-
mens [6], as was the case in the present report. As an
example, in the laboratory setting, cross-contamination
events may occur in the safety cabinet when a smear-pos-
itive specimen is handled in parallel with a smear-nega-
tive specimen, or during the phenotypic identification of
isolates during the niacin test [15]. Cross-contamination
of respiratory tract specimens by the avirulent M. tubercu-
losis H37Ra reference strain has also been reported [21].
The MST method, which was used in this study in addi-
tion to the more commonly used VNTR/MIRU typing
method [15,16], requires a relatively small amount of
sample DNA from the patient. In contrast to the conven-
tional IS6110-RFLP method, which requires a relatively
large amount of DNA, both the MST and the VNTR/MIRU
typing methods require only small DNA samples as they
are based on PCR amplification of selected genomic
regions [22]. The fact that such a small amount of material
is handled during these aforementioned procedures is an
obvious advantage, since it limits the risk of exposure of
Distribution of the MST profiles among M. tuberculosis isolates performed at different times in a laboratory Figure 1
Distribution of the MST profiles among M. tuberculosis isolates performed at different times in a laboratory.BMC Microbiology 2009, 9:47 http://www.biomedcentral.com/1471-2180/9/47
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laboratory personnel to a dangerous pathogen. Since the
MST method is based on sequence analysis, is reproduci-
ble and is easily exchangeable, we propose and offer a free
and accessible M. tuberculosis MST database (at http://
ifr48.timone.univ-mrs.fr/MST_MTuberculosis/mst) so
that microbiologists may compare the spacer sequence
profiles they obtain with previously determined profiles
for M. tuberculosis. The requirement for sequence analysis
may limit the diffusion of MST to those laboratories that
are equipped with an automatic sequencer, which is not a
commonality in most laboratories, especially those in
resource-limited countries.
Since MST uses PCR amplification as the first experimen-
tal step, it has the advantage of being applicable to DNA
extracts from inactivated mycobacterial cultures [23]
shortly after they are shown to be positive. The MST
results were obtained in four working days (from the
moment the culture was obtained to the interpretation of
MST analysis). A similar, yet slightly longer delay of 13
days (median value) between initial analysis and interpre-
tation of results was recently reported when using the
VNTR/MIRU method. In contrast, the conventional
IS6110 technique provided results in a median time of 45
days [16]. The delay period required to complete the MST
analysis is certainly short enough to contribute to the
interpretation of laboratory data that may have a signifi-
cant clinical impact on patients.
Conclusion
Our report confirms the importance of rapid identifica-
tion of cross-contamination. Indeed, the misdiagnosed
patient received unnecessary anti-tuberculosis therapy
and the final correct diagnosis was slightly delayed. MST
typing proved to be an efficient new tool for the detection
of cross-contamination with M. tuberculosis. In addition,
MST results may be obtained within a few days, which sig-
nificantly improves the quality of laboratory processing
and, therefore, the quality of medical care for the patient.
Methods
Epidemiological investigation
We reviewed laboratory charts to identify mycobacterial
isolates that were identified as M. tuberculosis during the 2-
week period before and after the isolation of M. tuberculo-
sis in the index patient (total study period, 4 weeks). We
carefully reviewed the batch number of each of these iso-
lates in order to pinpoint the day on which clinical speci-
mens were handled for setting in culture, as well as any
epidemiological links between patients.
Multispacer sequence typing
Isolates were identified using conventional methods [24]
and, after proper inactivation [23], by sequencing of the
ETR-D spacer, as previously described [18]. The MST gen-
otyping, PCR amplification and sequence analysis of eight
intergenic spacers were performed as described previously
[17]. Two negative controls consisting of the PCR mix in
the absence of the target DNA template were also per-
formed. Purified PCR products were sequenced by use of
the BigDye Terminator 1.1 Cycle Sequencing kit (Applied
Biosystems, Courtaboeuf, France). Sequencing electro-
phoresis was performed using a 3130 Genetic Analyser
(Applied Biosystems). Sequences were aligned using
CLUSTAL W http://pbil.ibcp.fr and compared to each
other and with a local database of M. tuberculosis spacer
sequences that is freely available on our website http://
ifr48.timone.univ-mrs.fr/MST_Mtuberculosis/mst. This
study was approved by the local Ethics Committee, Mar-
seille, France.
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